BioLineRx Ltd.

Equities

BLRX

IL0011015182

Biotechnology & Medical Research

Delayed TEL AVIV STOCK EXCHANGE Other stock markets 03:48:31 2024-06-03 EDT			5-day change	1st Jan Change
18.7 ^ILa	+2.19%		+8.72%	-51.05%

05-30	BioLineRx Ltd Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapy Applications in Sickle Cell Disease	CI
05-28	Transcript : BioLineRx Ltd., Q1 2024 Earnings Call, May 28, 2024

Biolinerx Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021

May 26, 2021 at 07:00 am

BioLineRx Ltd. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced operating loss was USD 5.449 million compared to USD 6.840 million a year ago. Net loss was USD 10.192 million compared to USD 6.645 million a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.04 a year ago.

Latest news about BioLineRx Ltd.

BioLineRx Ltd Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapy Applications in Sickle Cell Disease	05-30	CI
Transcript : BioLineRx Ltd., Q1 2024 Earnings Call, May 28, 2024	05-28
BioLineRx Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-28	CI
BioLineRx Ltd. Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer at American Society of Clinical Oncology	05-24	CI
BioLineRx Ltd. Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists Including APHEXDA® (Motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting	04-17	CI
BioLineRx Ltd. Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement	04-10	CI
BioLineRx Shares Fall After $6 Million Registered Direct Offering	04-01	MT
Transcript : BioLineRx Ltd., Q4 2023 Earnings Call, Mar 26, 2024	03-26
BioLineRx Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26	CI
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (Bl-8040) Suitable for Large Scale Production	03-04	CI
Biolinerx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer	02-28	CI
BioLineRx Ltd. Announces Acceptance of Two Poster Presentations on APHEXDA®? (Motixafortide) for CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT®?	02-16	CI
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease	12-21	CI
BioLineRx Ltd. Appoints Gal Cohen to Its Board as a Class I Director	12-12	CI
Transcript : BioLineRx Ltd., Q3 2023 Earnings Call, Nov 20, 2023	11-20
BioLineRx Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-20	CI
BioLineRx Signs License Agreement With GloriaBio for Multiple Myeloma Drug	23-10-12	MT
Biolinerx Ltd. Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment	23-10-12	CI
BioLineRx Ltd. announced that it has received $14.6 million in funding	23-10-11	CI
BioLineRx Says Pilot Phase of Combination Trial With Motixafortide in First-Line Pancreatic Cancer Yields 'Encouraging' Data	23-09-28	MT
Biolinerx Ltd. Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer	23-09-28	CI
HC Wainwright Raises BioLineRx's Price Target to $21 From $19, Maintains Buy Rating	23-09-15	MT
Transcript : BioLineRx Ltd. - Special Call	23-09-12
BioLineRx Shares Climb 22% After FDA Approves Aphexda With Filgrastim	23-09-11	DJ
BioLineRx Gets FDA Approval for Aphexda With Filgrastim	23-09-11	DJ

Chart BioLineRx Ltd.

Duration

Period

More charts

Company Profile

BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for BioLineRx Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOLINERX LTD.	-51.05%	59.09M
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.03%	21.96B
GENMAB A/S	-8.96%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B
INSMED INCORPORATED	+77.64%	8.87B

Bio Therapeutic Drugs